Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 08, 2016 2:24 PM ET


Company Overview of Profectus Biosciences, Inc.

Company Overview

Profectus Biosciences, Inc., a clinical-stage biotechnology company, designs and develops preventive and therapeutic vaccines. It develops products based on its platform PBS Vax, a prime/boost system of vaccines. The company’s products include GeneVax prime/VesiculoVax boost therapeutic HIV vaccines; and PBS Vax therapeutic vaccines for the treatment of chronic infectious diseases, such as HIV, HPV, HBV, HCV, and HSV-2. Its products also comprise VesiculoVax prophylactic vaccines for public health and biodefense, including Ebola/Marburg, EEVs, Chikungunya, and Lassa; and prophylactic vaccines, such as HIV and Nipah/Hendra vaccines. Profectus Biosciences, Inc. was formerly known as Maryland B...

6411 Beckley Street

Suite 202

Baltimore, MD 21224

United States

Founded in 2002





Key Executives for Profectus Biosciences, Inc.

President and Director
Executive Chairman
Executive Director of Operations and Outsourcing
Chief Scientific Officer of Vaccines
Corporate Counsel
Compensation as of Fiscal Year 2015.

Profectus Biosciences, Inc. Key Developments

Profectus BioSciences Initiates Ebola Vaccine Phase 1 Clinical Trial

Profectus BioSciences, Inc. announced the initiation of a Phase 1 clinical study of Profectus' VesiculoVax™-vectored Ebola virus vaccine. The vaccine is a version of the company's patented VSV vector that has been engineered for safe use in humans and to express the surface protein of Ebola virus. In preclinical studies, a single dose of this vaccine completely protected monkeys against the strain of Ebola virus responsible for the recent outbreak in West Africa. The Phase 1, placebo-controlled, dose-escalation study will enroll 39 subjects into three groups that will receive progressively higher doses of the vaccine by intramuscular injection. The trial is designed to establish the safety and immunogenicity of the vaccine at dose levels that span the dose shown to protect monkeys. The Profectus Ebola vaccine programs are supported by the U.S. Department of Defense Medical Countermeasures Systems–Joint Vaccine Acquisition Program (MCS-JVAP) both directly and through contracts with Battelle, the Biomedical Advanced Research and Development Authority (BARDA), and the National Institutes of Health (NIH).

Profectus BioSciences, Inc. Announces the Results of Study Demonstrating That Single Dose of Vaccine Administered Using the VesiculoVax Vector Platform

Profectus BioSciences, Inc. announced the results of a study demonstrating that a single dose of vaccine administered using the company's VesiculoVax vector platform protects non-human primates against challenge with the 'Makona' strain of Ebola virus (previously referred to as the Ebola Guinea strain) that is responsible for the current Ebola outbreak in West Africa. Results of the study are published in the April 9, 2015 issue of the journal, Nature, in an article entitled, 'Single-Dose Attenuated VesiculoVax Vaccines Protect Primates Against Ebola Makona Virus.' The study was authored by researchers at Profectus and the University of Texas Medical Branch (UTMB) at Galveston. In this trial, two candidate VesiculoVax-vectored Ebola vaccines of intermediate and high attenuation were tested, and both were shown to provide complete, single-dose protection of rhesus macaques against illness and death from the Makona strain of Ebola from Guinea, which is responsible for the current outbreak in West Africa. Eight vaccinated and two unvaccinated control macaques were infected with a Makona strain of Ebola virus 28days after receiving a single injection of one of the vaccines. None of the monkeys vaccinated with either vaccine showed any severe signs of illness following infection with the virus, whereas the two unvaccinated animals succumbed to the disease on days seven and eight. Profectus' highly attenuated rVSVN4CT1 VesiculoVax vector used in this study is also the foundation of the Profectus Ebola and Marburg monovalent and trivalent vaccines in development by Profectus with support from the National Institutes of Health (NIH), the U.S. Department of Health and Human Services (HHS) Biomedical Advanced Research and Development Authority (BARDA), and the Department of Defense (DoD) Joint Vaccine Acquisition Program (JVAP). The VesiculoVax platform provides the flexibility to construct vaccine delivery vectors with different levels of attenuation, a capability that enables the identification of vaccines that provide complete protection with level of safety.

Profectus Biosciences, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

Profectus Biosciences, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Similar Private Companies By Industry

Company Name Region
Selventa, Inc. United States
Keraplast Technologies Ltd. United States
Neoantigenics, Inc. United States
GeneExcel, Inc. United States
Alexar Therapeutics, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Profectus Biosciences, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at